Published in Circulation on July 17, 2001
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest (2009) 4.39
Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. J Clin Invest (2006) 3.22
The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest (2002) 2.26
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest (2001) 2.19
Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Circulation (2010) 2.15
The pathogenesis of cardiac fibrosis. Cell Mol Life Sci (2013) 1.96
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation (2004) 1.72
Simvastatin preserves diastolic function in experimental hypercholesterolemia independently of its lipid lowering effect. Atherosclerosis (2011) 1.59
Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation (2003) 1.56
Mechanisms of disease: hypertrophic cardiomyopathy. Nat Rev Cardiol (2011) 1.55
Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation (2013) 1.48
Modifier genes for hypertrophic cardiomyopathy. Curr Opin Cardiol (2002) 1.47
Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. Circulation (2004) 1.35
Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res (2005) 1.34
Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation (2009) 1.30
Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart (2005) 1.26
Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol (2006) 1.25
Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest (2010) 1.17
Contemporary treatment of hypertrophic cardiomyopathy. Tex Heart Inst J (2009) 1.12
Transgenic rabbit model for human troponin I-based hypertrophic cardiomyopathy. Circulation (2005) 1.04
A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy. Proc Natl Acad Sci U S A (2015) 1.04
Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy. J Mol Cell Cardiol (2004) 1.03
Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol (2010) 0.97
A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med (2003) 0.97
Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes. J Mol Cell Cardiol (2010) 0.96
Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis (2013) 0.95
Hypertrophic cardiomyopathy. Heart Fail Clin (2010) 0.95
Genetics and disease of ventricular muscle. Cold Spring Harb Perspect Med (2014) 0.92
Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein. J Mol Cell Cardiol (2011) 0.92
Identifying genes for coronary artery disease: An idea whose time has come. Can J Cardiol (2007) 0.90
Experimental therapies in hypertrophic cardiomyopathy. J Cardiovasc Transl Res (2009) 0.90
Pulmonary artery banding alters the expression of Ca2+ transport proteins in the right atrium in rabbits. Am J Physiol Heart Circ Physiol (2009) 0.89
Simvastatin inhibits TGFβ1-induced fibronectin in human airway fibroblasts. Respir Res (2011) 0.89
Induction and reversal of cardiac phenotype of human hypertrophic cardiomyopathy mutation cardiac troponin T-Q92 in switch on-switch off bigenic mice. J Am Coll Cardiol (2004) 0.89
Signaling to cardiac hypertrophy: insights from human and mouse RASopathies. Mol Med (2012) 0.88
Targeting cardiac fibrosis: a new frontier in antiarrhythmic therapy? Am J Cardiovasc Dis (2011) 0.87
Modeling human disease phenotype in model organisms: "It's only a model!". Circ Res (2011) 0.86
MiR-451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1. J Cell Mol Med (2014) 0.84
Statins Do Not Reduce Atrial Fibrillation After Cardiac Valvular Surgery: A Single Centre Observational Study. Neth Heart J (2010) 0.84
The diagnosis and treatment of hypertrophic cardiomyopathy. Dtsch Arztebl Int (2011) 0.84
On predictors of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol (2003) 0.83
Exercise training does not improve myocardial diastolic tissue velocities in Type 2 diabetes. Cardiovasc Ultrasound (2007) 0.83
Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial. J Card Fail (2011) 0.83
The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst. J Negat Results Biomed (2005) 0.82
Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease. Nat Rev Drug Discov (2016) 0.82
Transgenic rabbit models for studying human cardiovascular diseases. Comp Med (2012) 0.81
Cardiac fibrosis as a determinant of ventricular tachyarrhythmias. J Arrhythm (2014) 0.80
p90 ribosomal S6 kinase 3 contributes to cardiac insufficiency in α-tropomyosin Glu180Gly transgenic mice. Am J Physiol Heart Circ Physiol (2013) 0.80
Echocardiographic and electrocardiographic analyses of patients with severe motor and intellectual disabilities. Heart Vessels (2009) 0.79
Simvastatin alleviates cardiac fibrosis induced by infarction via up-regulation of TGF-β receptor III expression. Br J Pharmacol (2015) 0.79
Myosin binding protein C: implications for signal-transduction. J Muscle Res Cell Motil (2011) 0.79
To screen or not is not the question--it is when and how to screen. Circulation (2003) 0.79
Genetics and Genomics of Single-Gene Cardiovascular Diseases: Common Hereditary Cardiomyopathies as Prototypes of Single-Gene Disorders. J Am Coll Cardiol (2016) 0.79
Spectrum of pleiotropic effects of statins in heart failure. Heart Fail Clin (2008) 0.78
Simvastatin modulates remodeling of Kv4.3 expression in rat hypertrophied cardiomyocytes. Int J Biol Sci (2012) 0.78
Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids. J Hepatol (2010) 0.78
Therapeutic strategies for diastolic dysfunction: a clinical perspective. J Cardiovasc Ultrasound (2009) 0.77
Debate: Statins should be used in patients with heart failure. Curr Control Trials Cardiovasc Med (2001) 0.76
Simvastatin attenuates the oxidative stress, endothelial thrombogenicity and the inducibility of atrial fibrillation in a rat model of ischemic heart failure. Int J Mol Sci (2014) 0.76
Can heart function lost to disease be regenerated by therapeutic targeting of cardiac scar tissue? Semin Cell Dev Biol (2016) 0.75
Simvastatin offers new prospects for the treatment of Duchenne muscular dystrophy. Rare Dis (2016) 0.75
Statin Induced Regression of Cardiomyopathy Trial: A Randomized, Placebo-controlled Double-blind Trial. Heart Views (2017) 0.75
Update on hypertrophic cardiomyopathy. Tex Heart Inst J (2010) 0.75
Molecular biology of heart disease. World J Cardiol (2011) 0.75
Chamber-specific differences in human cardiac fibroblast proliferation and responsiveness toward simvastatin. Am J Physiol Cell Physiol (2016) 0.75
Echocardiographic predictors of severe heart failure symptoms in hypertrophic cardiomyopathy patients with sinus rhythm. Trials (2008) 0.75
Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA (1996) 7.03
Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol (1999) 5.01
Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol (1998) 4.44
Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med (1992) 4.20
Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation (2001) 3.33
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation (2001) 3.21
The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol (2001) 2.83
Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet (2000) 2.57
Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation (1999) 2.50
Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res (2000) 2.42
Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol (2000) 2.33
"Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res (1998) 2.30
A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest (1999) 2.19
Post-translational modifications of the C-terminal region of the rho protein are important for its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins. Oncogene (1991) 1.93
Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation (2000) 1.72
Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem (1996) 1.53
Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim Biophys Acta (1994) 1.45
3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res (1998) 1.31
Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis. Cardiovasc Res (1997) 1.23
Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol (1999) 1.17
Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol (1990) 1.15
Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am J Med (1989) 1.03
Phosphoinositide 3-kinase-dependent regulation of interleukin-3-induced proliferation: involvement of mitogen-activated protein kinases, SHP2 and Gab2. J Biol Chem (2001) 0.99
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase. Proc Natl Acad Sci U S A (1999) 0.99
Activation of extracellular-regulated kinases by normal and mutant EGF receptors. Biochim Biophys Acta (2001) 0.97
Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol (1999) 0.95
A controlled trial of teaching critical appraisal of the clinical literature to medical students. JAMA (1987) 14.20
Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol (1997) 8.98
Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest (2001) 7.20
Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation (1987) 5.73
Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med (1985) 5.09
Identification of a (CUG)n triplet repeat RNA-binding protein and its expression in myotonic dystrophy. Nucleic Acids Res (1996) 4.75
Identification of a genetic locus for familial atrial fibrillation. N Engl J Med (1997) 4.66
Second dose of measles, mumps, and rubella vaccine: questionnaire survey of health professionals. BMJ (2001) 4.50
Determining optimal therapy--randomized trials in individual patients. N Engl J Med (1986) 4.49
Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med (2001) 4.46
Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med (1998) 4.29
Synthesis of the yeast cell wall and its regulation. Annu Rev Biochem (1982) 4.26
Do sick newborn infants benefit from participation in a randomized clinical trial? J Pediatr (1999) 3.98
Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration. J Immunol (1999) 3.67
Comparison of percutaneous and surgical tracheostomies. Chest (1996) 3.56
A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography. Circulation (1981) 3.49
Myocardial ischemia and reperfusion: a murine model. Am J Physiol (1995) 3.38
WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell Mol Life Sci (2001) 3.38
A clinician's guide for conducting randomized trials in individual patients. CMAJ (1988) 3.35
Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation (2001) 3.33
Verifying quality and safety in health informatics services. BMJ (2001) 3.31
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation (2001) 3.21
Mutations in the lactose operon caused by bacteriophage Mu. J Mol Biol (1972) 3.17
The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology (1994) 2.95
Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Investigators of the Ontario Clinical Oncology Group. Int J Radiat Oncol Biol Phys (1994) 2.86
Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. J Allergy Clin Immunol (1982) 2.84
The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol (2001) 2.83
Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation (1995) 2.78
A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med (1990) 2.73
Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: clinical validation of two new methods using the apical window. Circulation (1984) 2.71
LFA-1 is sufficient in mediating neutrophil emigration in Mac-1-deficient mice. J Clin Invest (1997) 2.71
A standard heparin nomogram for the management of heparin therapy. Arch Intern Med (1991) 2.69
It's time for a change to a troponin standard. Circulation (2000) 2.69
The impact of socioeconomic status on health functioning as assessed by the SF-36 questionnaire: the Whitehall II Study. Am J Public Health (1997) 2.65
Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination. Am J Psychiatry (1991) 2.61
Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation (1999) 2.59
Doppler estimation of left ventricular filling pressure in sinus tachycardia. A new application of tissue doppler imaging. Circulation (1998) 2.55
Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation (1999) 2.50
Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature (1990) 2.46
A chronic mouse model of myocardial ischemia-reperfusion: essential in cytokine studies. Am J Physiol Heart Circ Physiol (2000) 2.42
Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet (1993) 2.38
Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation (1998) 2.37
APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology (2011) 2.35
Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators. Circulation (1991) 2.33
Relation of mean right atrial pressure to echocardiographic and Doppler parameters of right atrial and right ventricular function. Circulation (1996) 2.27
Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A (2000) 2.25
Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction system disease with childhood onset and absence of cardiac hypertrophy. Circulation (2001) 2.25
Mac-1 (CD11b/CD18) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils. J Immunol (1990) 2.24
Novel proteins with binding specificity for DNA CTG repeats and RNA CUG repeats: implications for myotonic dystrophy. Hum Mol Genet (1996) 2.23
Differentiating thrombus from pannus formation in obstructed mechanical prosthetic valves: an evaluation of clinical, transthoracic and transesophageal echocardiographic parameters. J Am Coll Cardiol (1998) 2.21
A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest (1999) 2.19
Electrocardiographic and clinical criteria for recognition of acute myocardial infarction based on analysis of 3,697 patients. Am J Cardiol (1983) 2.18
MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. Hum Mol Genet (2007) 2.17
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Development and implementation of guidelines for family practice: lessons from The Netherlands. J Fam Pract (1995) 2.11
Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation (1999) 2.09
Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation (2000) 2.05
Dobutamine echocardiography in myocardial hibernation. Optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Circulation (1995) 2.04
Hemodynamic determinants of the mitral annulus diastolic velocities by tissue Doppler. J Am Coll Cardiol (2001) 2.04
Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. BMJ (1993) 2.03
Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. Circulation (1990) 2.01
Isolation and sequence analysis of a full-length cDNA for human M creatine kinase. Biochem Biophys Res Commun (1986) 1.96
Invited letter concerning: neutrophil activation during cardiopulmonary bypass. J Thorac Cardiovasc Surg (1991) 1.93
Stress echocardiography: recommendations for performance and interpretation of stress echocardiography. Stress Echocardiography Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr (1998) 1.92
Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci U S A (1989) 1.90
Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation (1998) 1.88
Integrated patient records: another move towards quality for patients? Qual Health Care (1993) 1.88
Quantification of atrial contribution to left ventricular filling by pulsed Doppler echocardiography and the effect of age in normal and diseased hearts. Am J Cardiol (1987) 1.87
Does breastfeeding at six months predict cognitive development? Aust N Z J Public Health (1998) 1.87
Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst (1996) 1.86
Neutrophil transendothelial migration is independent of tight junctions and occurs preferentially at tricellular corners. J Immunol (1997) 1.84
Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival. Proc Natl Acad Sci U S A (2001) 1.83
Relation of tissue Doppler derived myocardial velocities to myocardial structure and beta-adrenergic receptor density in humans. J Am Coll Cardiol (2000) 1.82
Depression and risk of sudden cardiac death after acute myocardial infarction: testing for the confounding effects of fatigue. Psychosom Med (2000) 1.80
Familial colloid cyst of the third ventricle: case report and review of associated conditions. Neurosurgery (1996) 1.79
Cytoplasmic Ca2+ does not inhibit the cardiac muscle sarcoplasmic reticulum ryanodine receptor Ca2+ channel, although Ca(2+)-induced Ca2+ inactivation of Ca2+ release is observed in native vesicles. J Membr Biol (1993) 1.78
An improved basis for enzymatic estimation of infarct size. Circulation (1975) 1.77
Determination of parameters of left ventricular diastolic filling with pulsed Doppler echocardiography: comparison with cineangiography. Circulation (1985) 1.77
The influence of location and extent of myocardial infarction on long-term ventricular dysrhythmia and mortality. Circulation (1979) 1.75
Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ Res (2001) 1.74
Exercise echocardiography versus 201Tl single-photon emission computed tomography in evaluation of coronary artery disease. Analysis of 292 patients. Circulation (1992) 1.74
Myofibroblasts in reperfused myocardial infarcts express the embryonic form of smooth muscle myosin heavy chain (SMemb). Cardiovasc Res (2000) 1.73
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation (2004) 1.72
ABC of child abuse. Child sexual abuse--II. BMJ (1989) 1.72
Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation (2000) 1.72